Indegene Posts Strong Q3 FY26 Revenue Growth of Over 30 Percent

  1. Home  > Business  > 
  2. Indegene Posts Strong Q3 FY26 Revenue Growth of Over 30 Percent
30, Jan 2026
Indegene Posts Strong Q3 FY26 Revenue Growth of Over 30 Percent

Bengaluru, India, Jan 30: Indegene, the tech-native, life sciences specialist, today announced its financial results for the quarter ended December 31, 2025, reporting robust growth and key strategic milestones.

Key Highlights – Q3 FY26:

  • Revenue grew 30.8% YoY and 17.1% QoQ, marking the company’s first $100 million+ revenue quarter.

  • Adjusted EBITDA rose 15.7% YoY and 19.6% QoQ, with a margin of 18.5%, reflecting strong operational efficiency.

  • Revenue per employee surpassed $70k, the highest in the industry.

  • Three of the top five customers expanded to $25 million+ annual revenue.

  • 52 customers now generate $1 million+ annual revenue.

  • Secured significant new contracts, including two deals exceeding $10 million ACV each and another exceeding $5 million ACV.

Strategic Developments:
During the quarter, Indegene completed the acquisitions of BioPharm, a US-focused life sciences omnichannel business, and Warn & Co., a UK-based consulting firm, strengthening the company’s domain expertise and high-value capabilities. Cash and investments remain healthy, supporting sustained growth and future strategic initiatives.

Leadership Commentary:
Manish Gupta, Chairman and CEO, Indegene, said:

“We delivered a standout Q3 FY26, with revenue growing over 30% YoY and 17% sequentially. Our revenue per employee crossing $70K underscores the impact of technology and AI in driving productivity. With 3 customers surpassing $25 million annual revenue and 52 customers exceeding $1 million, our client relationships are stronger than ever. Strategic wins this quarter combine execution strength with AI, positioning us for sustained, profitable growth.”

Suhas Prabhu, CFO, Indegene, added:

“EBITDA, adjusted for one-time expenses, grew strongly, reflecting operational discipline. While reported PAT remained flat due to transient acquisition-related costs and higher non-cash amortization, profitability is expected to strengthen as synergies are realized and growth momentum continues.”

Indegene’s Q3 performance reinforces its leadership in the life sciences sector and positions the company to continue delivering innovative, AI-driven solutions that generate measurable outcomes for its clients globally.